Filing Details
- Accession Number:
- 0001722482-21-000025
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-13 17:41:42
- Reporting Period:
- 2021-01-11
- Accepted Time:
- 2021-01-13 17:41:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1722482 | Avantor Inc. | AVTR | Laboratory Analytical Instruments (3826) | 822758923 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1776107 | Gerard Brophy | Radnor Corporate Center, Building One, Suite 200, 100 Matsonford Road Radnor PA 19087 | Evp, Biopharma Production | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-01-11 | 216,332 | $23.20 | 394,847 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-01-11 | 216,332 | $30.08 | 178,515 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-01-11 | 162,248 | $23.20 | 340,763 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-01-11 | 162,248 | $30.04 | 178,515 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Disposition | 2021-01-11 | 162,248 | $0.00 | 162,248 | $23.21 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 162,250 | 2028-07-30 | No | 4 | M | Direct |
Footnotes
- The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.33, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.00 to $30.21, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above
- Reflects an initial grant of 540,830 stock options in which 40% vested at the time of IPO and the remaining 60% that vests in four equal installments beginning on July 30, 2019.
Billionaire Hedge Funds
